Suchergebnisse - "Palmieri, Salvatore"

PubPharm (42)

1

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

enthalten in: The New England journal of medicine | 2024

von Sonneveld, P. | Dimopoulos, M. | Boccadoro, M. | +141

CommentIn: N Engl J Med. 2024 Apr 18;390(15):1440. - PMID 38631009

2

Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma : a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials

enthalten in: Haematologica | 2024

von Gentile, M. | Vigna, E. | Palmieri, S. | +44

3

Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders : A Multicenter Real-Life Experience

enthalten in: Targeted oncology | 2023

von De Novellis, D. | Fontana, R. | Palmieri, S. | +30

4

Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients : italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials

enthalten in: Hematological oncology | 2022

von Martino, E. | Conticello, C. | Zamagni, E. | +30

5

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma : Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

enthalten in: Hematological oncology | 2022

von Bruzzese, A. | Derudas, D. | Galli, M. | +57

6

High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Bertamini, L. | Oliva, S. | Rota-Scalabrini, D. | +26

CommentIn: J Clin Oncol. 2022 Sep 20;40(27):3099-3102. - PMID 35759726

7

Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients

enthalten in: European journal of haematology | 2022

von Morabito, F. | Zamagni, E. | Conticello, C. | +41

8

Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy : Analysis of 919 Cases Outside Clinical Trials

enthalten in: Frontiers in oncology | 2022

von Morabito, F. | Zamagni, E. | Conticello, C. | +45

9

Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients : A multicentric real-life experience

enthalten in: Frontiers in oncology | 2022

von Iula, R. | De Novellis, D. | Trastulli, F. | +21

10

KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life : a retrospective survey in 123 patients

enthalten in: Annals of hematology | 2020

von Palmieri, S. | Rocco, S. | Vitagliano, O. | +17

1
2
3
4
5
Nächster »
[5]